The academic path of Filipe Pereira has taken him from Portugal to London, New York and finally to Sweden. He is currently leading a research team of 15 scientists and receives funding from major European and Swedish research foundations including the ERC consolidator grant, the Swedish research council consolidator grant, Novo Nordisk foundation and the Swedish cancer foundation. 

Filipe Pereira’s research is directly linked to the focus of the Wallenberg Centre of Molecular Medicine in Lund. He and his team are trying to understand how cell identity is acquired, maintained, and how it can be modified and exploited for treatment. During his time in Lund, Filipe Pereira has pioneered cell fate reprogramming in immunology with dendritic cells.

He co-founded two startup companies, BRT blood reprogramming technologies and Asgard Therapeutics, both based on cellular reprogramming. Besides his commitment being part of the working groups at Lund University for the development of ATMPs and the national CAMP network, he is also part of the WCMM working group in Lund. 

Along his way Filipe Pereira has established a strong academic and industrial network nationally and globally, and he is now taking the next step in his career being a full professor at Lund University. 

Congratulations Filipe!